Earnings Summary

TCR2 Therapeutics, Inc.’s revenue jumped NaN% since last year same period to $0Mn in the Q3 2020. On a quarterly growth basis, TCR2 Therapeutics, Inc. has generated NaN% jump in its revenue since last 3-months.

TCR2 Therapeutics, Inc.’s net profit fell -22.57% since last year same period to $-16.92Mn in the Q3 2020. On a quarterly growth basis, TCR2 Therapeutics, Inc. has generated -4.17% fall in its net profits since last 3-months.

TCR2 Therapeutics, Inc.’s net profit margin jumped NaN% since last year same period to -Inf% in the Q3 2020. On a quarterly growth basis, TCR2 Therapeutics, Inc. has generated NaN% jump in its net profit margins since last 3-months.

TCR2 Therapeutics, Inc.’s earning per share (EPS) estimates for the current quarter stand at -0.8 - a -6.08% fall from last quarter’s estimates.

TCR2 Therapeutics, Inc.’s earning per share (EPS) estimates for the current year stand at -0.8.

TCR2 Therapeutics, Inc.’s earning per share (EPS) fell -14.49% since last year same period to -0.79 in the Q3 2022. This indicates that the TCR2 Therapeutics, Inc. has generated -14.49% annual rate of fall in its earning per share (EPS) in the last 4 quarters.

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. TCR2 Therapeutics, Inc.’s return on assets (ROA) stands at -0.23.

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. TCR2 Therapeutics, Inc.’s return on equity (ROE) stands at -0.47.